MTAP Underexpression

CI-VAR-00004413Explore in graph →CIViC 867

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
MTAP Underexpression AND CDKN2A Underexpression	Pemetrexed	Predictive	B	Supports Sensitivity Response	2	submitted	EID12723 In a retrospective cohort of metastatic lung adenocarcinoma from the BATTLE-2 trial (n = 72), patients with CDKN2A and MTAP co-underexpression tumors (n = 26; representative for 9p21 loss) demonstrate… (full text at CIViC) PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC	civic
Malignant Breast Neoplasm1
MTAP Underexpression	Pyrimidine Antagonist	Predictive	D	Supports Sensitivity Response	1	accepted	EID1980 MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expression as well as promoter methylation status were analyzed in breast cancer patients and seven breast cancer cell lines. Knockdown of… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.